In the most recent filing that the company made with the Securities and Exchange Commission, it was disclosed that Kornitzer Capital Management Inc. KS decreased its TransMedics Group, Inc. (NASDAQ: TMDX) shares by 23.3% during the third quarter (SEC). The corporation had 392,926 shares at the time of sale, having previously sold 119,468 of those shares during the relevant period. The most recent accounting period concluded with Kornitzer Capital Management Inc. having ownership of the TransMedics Group to the tune of $16,401,000 as of the end of the period.
In the most recent few months, several other significant investors have made adjustments to the positions that they currently hold in TMDX. During the second quarter, Prospera Financial Services Inc. acquired a new holding that included approximately 69,000 dollars worth of shares issued by TransMedics Group. During the first three months of the year, Amalgamated Bank made a contribution to TransMedics Group for 114,000 dollars. Raymond James & Associates invested in TransMedics Group with a total value of 228,000 dollars during the third quarter of the fiscal year. Ziegler Capital Management LLC increased the total amount of money it had invested in TransMedics Group by $235,000 during the third quarter of the fiscal year.
Last but not least, the value of the investment that Captrust Financial Advisors had made in TransMedics Group increased by 738% during the first quarter of this year. Captrust Financial Advisors acquired an additional 5,098 shares throughout the period. This brings the total number of shares they own in the company to 5,788, which has a value of $156,000. Most of the company’s stock is held in the hands of institutional investors, accounting for 88.58% of the total.
David Weill, a director at TransMedics Group, carried out a transaction on November 10 in which he sold 21,645 shares of the company’s stock. The transaction was completed successfully. In the market, a total of 1,212,120.00 worth of shares were traded at an average price of $56.00 per share, making the total number of shares traded 1,212,120.00 worth. Following the successful sale conclusion, the director is now the owner of 13,500 business shares with an estimated value of $756,000. The Securities and Exchange Commission was given legal documents about the transaction, which were subsequently uploaded to the SEC website after being provided to the SEC. In addition, it is important to note that on November 10, director David Weill sold 21,645 shares of stock in TransMedics Group. This is an important event to take note of. A total of 1,212,120.00 dollars’ worth of stock was traded at an average price of $56.00 per share, which brings the total amount of money involved to 1,212,120.00 dollars. Following the completion of the transaction, the director will have a direct ownership stake in 13,500 shares of the company’s stock, which will be worth approximately $756,000. The transaction was disclosed to the public through a filing that was made with the SEC, which can be located on the website of the SEC. In addition, on November 7, the company’s Chief Executive Officer, Waleed H. Hassanein, sold 2,769 shares of the company’s stock. The sale of the shares brought in a total of $166,333.83 in revenue, with the average price at which each share was sold being $60.07. Following the conclusion of the transaction, the Chief Executive Officer currently has a personal holding of 443,516 shares of the company, which have a combined value of $26,642,006.12. Disclosures that are related to the sale might be found in this section of the website. Insiders sold 116,373 company stock during the most recent ninety days, bringing the total value of those sales to $6,904,458, or 8.70% of the total number of active shares in the company.
Several equity research professionals have expressed their thoughts on the TMDX stock.
Cowen raised their price target on TransMedics Group from $60.00 to $70.00 in a research report that was published on Friday, December 16. This increase was done to reflect the bullish outlook that the company currently possesses. Morgan Stanley increased its price objective on TransMedics Group from $54.00 to $63.00 in a research report published on Friday, January 6. Additionally, an “equal weight” rating was given to the stock by the company. Canaccord Genuity Group raised their target price on shares of TransMedics Group from $58.00 to $63.00 and upgraded the company from a “hold” rating to a “buy” rating in a research report published on November 4. There have been six analysts that have assigned a buy rating to the company, while there has only been one analyst that has assigned a hold recommendation to the stock. According to the data provided by Bloomberg, the company is currently rated as having an average “Moderate buy” recommendation with a price target of $53.29.
After a total gain of $1.65 throughout the Friday trading day, the TMDX reached $62.84 before the market closed. Only 3,303 of the company’s shares were traded, a significantly lower volume than the typical volume of 2,983,19 shares traded. The company has a debt-to-equity ratio of 0.31, a quick ratio of 11.21, and a current ratio of 12.11 in its financial statements. The stock price has a simple moving average of $59.06 over the past 50 days, while its price has a simple moving average of $49.47 over the past 200 days. During the previous calendar year, the price of a share of TransMedics Group, Inc. fell as low as $10.00, while it reached an all-time high of $65.47. The company’s price-to-earnings ratio is -43.43, and its beta value is 1.57. The value of the company’s beta is 1.57. The company has a market capitalization of $2.01 billion at the moment.
The financial report for TransMedics Group, which is publicly traded and can be found on NASDAQ under the symbol TMDX, was made available to the public on November 3. The company announced earnings for the quarter of $0.25 per share, which was $0.15 higher than the consensus estimate of earnings for the quarter among industry analysts, who had predicted earnings of $0.40 per share. The return on equity and the net margin for the company was negative for TransMedics Group. The return on equity was -46.03%, and the net margin was -58.78%. The company’s quarterly revenue was significantly higher than expected, coming in at $25.68 million, despite analysts’ predictions that the company would only bring in $18.96 million in sales for the period. This year, it is anticipated that TransMedics Group, Inc. will bring in a revenue of $1.3 per share, according to the projections of market analysts.
The company specializing in medical technology, TransMedics Group, Inc., has moved into the commercial stage. The company is currently marketing the foundation for an organ care system even though it is in the process of actually building the system itself. It does this by concentrating on preserving human organs for transplant in a nearly physiologic state, thereby overcoming the limitations of organ preservation methods that rely on cold storage. This makes it possible to put the organs to use more timely.